GlassScriptPhysician profile
Alireza Tabesh
NPI 1356482392
$9,491.17
in general payments reported to CMS, 2019-2025
22 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $670 · 2021: $848 · 2022: $2,948 · 2023: $1,632 · 2024: $1,647 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,709 · Education: $103 · Debt Forgiveness: $16.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,708.91 |
| Education | $102.58 |
| Debt Forgiveness | $16.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $2,902.67 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,808.36 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,298.75 | 2022-2025 | Tremfya, Stelara |
| Ironwood Pharmaceuticals, INC | $1,164.54 | 2019-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $448.92 | 2019-2022 | |
| Abbvie INC. | $383.58 | 2020-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $333.92 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $290.46 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Celgene Corporation | $243.54 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $161.73 | 2020-2024 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $96.90 | 2021-2024 | Dificid |
| Novo Nordisk INC | $76.03 | 2025 | Wegovy |
| Bioventus LLC | $48.09 | 2024-2025 | Exogen Ultrasound Bone Healing System |
| Enterra Medical, INC. | $43.63 | 2025 | |
| Exact Sciences Corporation | $41.68 | 2024-2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $28.10 | 2019 | |
| Shionogi INC | $23.07 | 2019 | |
| Echosens North America, INC. | $22.27 | 2025 | Fibroscan |
| Fresenius Kabi USA, LLC | $20.83 | 2023 | |
| Intercept Pharmaceuticals, INC. | $20.28 | 2021 | |
| Celltrion USA INC. | $17.59 | 2024 | Zymfentra |
| Baxter Healthcare | $16.23 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alireza Tabesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.